Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 15, 2007

Anaptys Biosciences Acquires IP for Antibody Discovery and Protein Optimization

  • Anaptys Biosciences obtained exclusive licenses to complementary somatic hypermutation technologies from the UK Medical Research Council (MRC) and the Albert Einstein College of Medicine of Yeshiva University (AECOM). Somatic hypermutation is the natural process our bodies use for generating antibody diversity to fight disease.

    Anaptys says its Omnitope-SHM™ System utilizes the key components of somatic hypermutation to enable the rapid variation and functional selection of evolved proteins with enhanced bioactivities.

    "The MRC and AECOM technologies augment Anaptys' in-house development of proprietary vectors and methods for creating antibodies and other proteins," says William Boyle, Ph.D., co-founder, president and CSO of Anaptys. "With our Omnitope-SHM System, we can tap into the sequence variations brought about by SHM to rapidly and efficiently discover and optimize antibodies for a diverse set of disease targets."



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »